| 研究課題/領域番号 |
22K09932
|
|---|
| 研究種目 |
基盤研究(C)
|
| 配分区分 | 基金 |
|---|
| 応募区分 | 一般 |
|---|
| 審査区分 |
小区分57020:病態系口腔科学関連
|
|---|
| 研究機関 | 日本大学 |
|---|
研究代表者 |
Cueno Marni 日本大学, 歯学部, 専修研究員 (20569967)
|
|---|
| 研究期間 (年度) |
2022-04-01 – 2025-03-31
|
| 研究課題ステータス |
交付 (2023年度)
|
| 配分額 *注記 |
4,290千円 (直接経費: 3,300千円、間接経費: 990千円)
2024年度: 1,040千円 (直接経費: 800千円、間接経費: 240千円)
2023年度: 1,560千円 (直接経費: 1,200千円、間接経費: 360千円)
2022年度: 1,690千円 (直接経費: 1,300千円、間接経費: 390千円)
|
|---|
| キーワード | SARS-CoV-2 spike / influenza HA / gingival vaccination / protein modelling / SARS-CoV-2 / influenza hemagglutinin / vaccine / SARS CoV 2 / Influenza |
|---|
| 研究開始時の研究の概要 |
Research Activity 1: Virulence factor entry through the gingival crevice can affect the body systemically by altering immune-related and ageing-related biochemical networks.
Research Activity 2: Virulence factor entry through the gingival crevice can affect the brain and nerve cells in vivo.
Research Activity 3: Identifying target amino acid residues in the SARS CoV 2 spike and influenza A/B hemagglutinin proteins that could affect structural evolution
and viral infection among seasonal and pandemic influenza strains.
Research Activity 4: Vaccination design and antigen production strategies.
|
| 研究実績の概要 |
We were able to design the molecular structures related to the following: SARS-CoV-2 spike protein, influenza A H3N2 hemagglutinin (HA) and H5N1 HA, and influenza B/Yamagata HA proteins. Additionally, we were also able to do in silico xanthan gel molecular docking and confirmed that protein epitopes associated with activating B- and T-cell immune responses are readily exposed after xanthan gel molecule docking. We were able to optimize the antigen:gel ratio for influenza A H3N2 HA, H5N1 HA, and influenza B/Yamagata HA while antigen:gel ratio optimization for SARS-CoV-2 spike proteins are on-going.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We successfully designed and produced all our desired target antigen proteins (SARS-CoV-2 alpha, beta, gamma, delta, omicron spike proteins, influenza A H3N2 HA, influenza A H5N1 HA, influenza B/Yamagata HA) in silico. Additionally, antigen:gel ratio optimization for influenza A H3N2 HA, influenza A H5N1 HA, influenza B/Yamagata HA were done while antigen:gel ratio optimization for SARS-CoV-2 alpha, beta, gamma, delta, and omicron spike proteins are on-going. Three manuscripts have been written and submitted to internationally peer-reviewed journals and are currently under review.
|
| 今後の研究の推進方策 |
Vaccination of the optimized antigen:gel ratio along the gingival crevice will be performed. ELISA (B-cell immunity) and ELISPOT (T-cell immunity) will be performed following previously published work. Immune response from all all protein antigens (SARS-COV-2 spike, influenza A HA, and influenza B HA) will be checked to establish immune efficacy of the gel vaccine. In addition, results will be compared to direct gingival, sublingual, oral, and intramuscular vaccination strategies.
|
